OncoSec to Present Encore Interim Data from the KEYNOTE-695 Phase 2b Clinical Trial at the 10th World Congress of Melanoma Apr 15, 2021 8:30am EDT
OncoSec Receives CE Mark Certification for its Commercial Electroporation Device "GenPulse™" for the Treatment of Solid Tumors Apr 14, 2021 8:30am EDT
OncoSec Medical Sponsoring KOL Webinar On A High Unmet Medical Need: Anti-PD-1 Checkpoint Refractory Metastatic Melanoma Mar 25, 2021 8:39am EDT
OncoSec Announces Publication in Clinical Cancer Research of Data Supporting the Therapeutic Potential of Lead Product Candidate, TAVO™, in Triple Negative Breast Cancer Mar 01, 2021 9:00am EST
OncoSec Appoints Bridget O'Keeffe, Ph.D. as Vice President of Clinical Development Feb 18, 2021 8:30am EST
OncoSec Announces First Subjects Dosed in Phase 1 Trial of CORVax12, OncoSec's COVID-19 Vaccine Candidate Combining Interleukin-12 (IL-12) with an Enhanced SARS-CoV-2 Spike Protein Jan 27, 2021 9:00am EST
OncoSec Medical Announces Pricing of $42.0 Million Public Offering of Common Stock Jan 21, 2021 8:30am EST
